Esavi relacionado a la vacuna-Pfizer contra SARS-COv-2(covid-19) en la unidad zonal de farmacovigilancia-Manabí y Santo-Domingo de los Tsáchilas.
Fecha
2022
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
Introducción: Los coronavirus (CoVs) son virus ARN monocatenarios, que causan trastornos respiratorios, digestivos, hepáticos y neurológicos de severidad variable en un amplio rango de especies animales, incluyendo al ser humano, son de gran interés en la comunidad científica, causante del síndrome respiratorio agudo severo (conocido como SARS-CoV). Objetivo: Analizar los eventos adversos relacionados a la administración de la vacuna-Pfizer contra SARS-CoV-
2 (COVID-19), que es notificada a la unidad zonal de farmacovigilancia de Manabí y Santo Domingo de los Tsáchilas, durante el periodo de estudio febrero a junio del 2021. Metodología: El presente estudio se aplicó una valoración de datos sobre notificaciones de ESAVI en relación a la vacuna SARS-CoV-2 (COVID-19), usando un método descriptivo- observacional, y de enfoque cuantitativo, el mismo que tuvo un diseño metodológico no experimental- transversal debido a que se determino la afectación de los eventos adversos relacionados con la vacuna-Pfizer contra SARS-CoV-2 (COVID-19); además, de los factores de riesgos notificados durante el periodo de estudio. Resultados: se determinaron 103 notificaciones de ESAVI de los cuales 12 se consideraron graves, donde la preexistencia de enfermedades respiratorias son factores de riesgo, el índice de población afectada difiere con la edad Conclusión: la vacuna Pfizer contra el coronavirus causó ESAVI de leve severidad en la unidad zonal de Manabí y Santo Domingo de los Tsáchilas.
Introduction: Coronaviruses (CoVs) are single-stranded RNA viruses that cause respiratory, digestive, liver and neurological disorders of variable severity in a wide range of animal species, including humans, they are of great interest in the scientific community, causing the syndrome severe acute respiratory tract (known as SARS-CoV). Objective: To analyze the adverse events related to the administration of the vaccine-Pfizer against SARS-CoV-2 (COVID-19), which is notified to the zonal pharmacovigilance unit of Manabí and Santo Domingo of the Tsachilas during the study period February to June of 2021. Methodology: In this titration study, an evaluation of data on ESAVI notifications in relation to the SARS-CoV-2 (COVID-19) vaccine was applied, using a descriptive-observational method, and with a quantitative approach, the same one that had a non- experimental-cross-sectional methodological design because the effect of adverse events related to the vaccine-Pfizer against SARS-CoV-2 and / or COVID-19 was determined; in addition to the risk factors reported during the study period. Results: there were103 ESAVI notifications determined of which 12 were considered serious, hence the preexistence of respiratory diseases are risk factors, the affected population index differs with the age Conclusion: the Pfizer vaccine against coronavirus caused ESAVI of mild severity in the Manabí and Santo Domingo de los Tsachilas zonal.
Introduction: Coronaviruses (CoVs) are single-stranded RNA viruses that cause respiratory, digestive, liver and neurological disorders of variable severity in a wide range of animal species, including humans, they are of great interest in the scientific community, causing the syndrome severe acute respiratory tract (known as SARS-CoV). Objective: To analyze the adverse events related to the administration of the vaccine-Pfizer against SARS-CoV-2 (COVID-19), which is notified to the zonal pharmacovigilance unit of Manabí and Santo Domingo of the Tsachilas during the study period February to June of 2021. Methodology: In this titration study, an evaluation of data on ESAVI notifications in relation to the SARS-CoV-2 (COVID-19) vaccine was applied, using a descriptive-observational method, and with a quantitative approach, the same one that had a non- experimental-cross-sectional methodological design because the effect of adverse events related to the vaccine-Pfizer against SARS-CoV-2 and / or COVID-19 was determined; in addition to the risk factors reported during the study period. Results: there were103 ESAVI notifications determined of which 12 were considered serious, hence the preexistence of respiratory diseases are risk factors, the affected population index differs with the age Conclusion: the Pfizer vaccine against coronavirus caused ESAVI of mild severity in the Manabí and Santo Domingo de los Tsachilas zonal.
Descripción
PDF
Palabras clave
COVID-19, EFECTOS ADVERSOS, NOTIFICACIONES, SARS-COV-2, VACUNA, PFIZER